Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 688,400 shares, an increase of 15.6% from the May 15th total of 595,600 shares. Currently, 5.1% of the shares of the stock are sold short. Based on an average trading volume of 74,500 shares, the short-interest ratio is presently 9.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Acurx Pharmaceuticals in a research note on Thursday, May 16th.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ACXP. Prospect Financial Services LLC acquired a new stake in Acurx Pharmaceuticals during the 4th quarter worth about $977,000. NBC Securities Inc. acquired a new stake in Acurx Pharmaceuticals during the 1st quarter worth about $34,000. Finally, Sigma Planning Corp acquired a new stake in Acurx Pharmaceuticals during the 4th quarter worth about $38,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Trading Down 2.1 %

Shares of ACXP opened at $2.38 on Tuesday. The business’s 50-day moving average price is $2.21 and its 200 day moving average price is $2.91. The stock has a market capitalization of $37.70 million, a P/E ratio of -2.02 and a beta of -1.70. Acurx Pharmaceuticals has a 1-year low of $1.17 and a 1-year high of $8.82.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). On average, research analysts predict that Acurx Pharmaceuticals will post -1.28 earnings per share for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.